sarilumab for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
Lescure (Sarilumab 200mg) NCT04327388		RCT	sarilumab low dose (200mg)	placebo	COVID-19 severe or critically	some concern	161/86	inconclusive	inconclusive 3 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Lescure (Sarilumab 400mg) NCT04327388		RCT	sarilumab	placebo	COVID-19 severe or critically	some concern	173/86	inconclusive
Lescure (Sarilumab 400mg) NCT04327388		RCT	sarilumab high dose (400mg)	placebo	COVID-19 severe or critically	some concern	173/86	inconclusive
2 studies excluded by filtering options (1 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis